Comparative Pharmacology
Head-to-head clinical analysis: ARIDOL KIT versus PYLORI CHEK BREATH TEST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIDOL KIT versus PYLORI CHEK BREATH TEST.
ARIDOL KIT vs PYLORI-CHEK BREATH TEST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mannitol, a sugar alcohol, acts as an osmotic diuretic and osmotic agent. It increases plasma osmolality, drawing water from tissues into the bloodstream and enhancing urinary excretion. In the respiratory tract, it is used as a bronchial challenge agent to induce bronchoconstriction in patients with asthma by increasing airway osmolality and triggering mast cell mediator release.
Urea labeled with 13C is hydrolyzed by urease enzyme produced by Helicobacter pylori, producing 13CO2 which is exhaled and detected in breath.
Aridol (mannitol) is administered via inhalation as a dry powder for bronchial challenge testing. The standard adult dose is a single capsule (25 mg) inhaled using the Aridol inhaler device, with doses escalated as per protocol (e.g., 5, 10, 20, 40 mg cumulative) until a 15% fall in FEV1 is achieved or maximum cumulative dose of 160 mg is reached.
Adults: 75 mg of 13C-urea dissolved in 75 mL of water, administered orally as a single dose. Breath samples collected at baseline and 30 minutes post-dose.
None Documented
None Documented
The terminal elimination half-life of mannitol is approximately 100 minutes (1.7 hours) in patients with normal renal function. This may be prolonged up to 36 hours in patients with renal impairment, necessitating dose adjustment.
The elimination half-life of 13C-urea is approximately 0.5–1 hour in patients with normal renal function, reflecting rapid renal clearance. In severe renal impairment, half-life may be prolonged up to 7–10 hours.
Mannitol (the active ingredient in Aridol Kit) is primarily excreted unchanged in the urine via glomerular filtration, with approximately 80-90% of an intravenous dose eliminated within 24 hours. Less than 10% is metabolized in the liver, and negligible amounts are eliminated in feces or bile.
13C-urea is excreted renally as intact urea (approximately 85%) and as 13CO2 in breath (approximately 15%). Fecal elimination is negligible. In renal impairment, breath 13CO2 excretion may increase as renal clearance decreases.
Category C
Category C
Diagnostic Agent
Diagnostic Agent